ArticleJournal of inflammation research2025
High-Dose Corticosteroids in Critically Ill COVID-19 Patients: A Retrospective Cohort Study from Suriname.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-dose corticosteroids (HDS) are established treatment for non-COVID-19 acute respiratory distress syndrome (ARDS) because of their anti-inflammatory effects. In COVID-19 patients requiring oxygen therapy or invasive mechanical ventilation, 6mg dexamethasone daily reduces mortality. In severe COVID-19 pneumonia, higher corticosteroid doses are sometimes administered in an attempt to reduce mortality. This study evaluated the effect of HDS compared to standard-dose dexamethasone on IC mortality and superinfection rates in Suriname. Methods: This retrospective cohort study included patients with PCR-confirmed severe COVID-19 pneumonia admitted to ICUs in Suriname, between June 2020 and October 2021. Data was analyzed from a random sample of patients extracted from a larger database originally collected for another ICU COVID-19 study. Patients received standard-dose corticosteroids (SDS) and/or HDS (dexamethasone >6 mg daily or equivalent). Treatment with HDS was analyzed as a time-dependent exposure. Predictors of mortality were identified through logistic regression and incorporated as covariates in a time-updated Cox survival model. Chi-square test compared bacterial superinfections between treatment groups. Results: Of 103 included patients, 36 (35%) received HDS. Invasive mechanical ventilation, septic shock, bacterial superinfection, creatinine elevation, age, CXR score, and P/F ratios were associated with mortality in univariable analysis. In multivariable analysis, only age (OR 1.10 per year, p=0.022) and invasive mechanical ventilation (OR 8.28, p=0.046) remained significant. Time-updated survival analysis showed no significant harm or benefit with HDS (HR 1.99, 95% CI:0.78-5.09, p=0.15) and no increased superinfection rates (p=1.00). Conclusion: This first Surinamese study of HDS in severe COVID-19 pneumonia found no improved outcomes compared to SDS, nor increased bacterial superinfections. Our findings do not support HDS escalation in this population. The identified mortality risk factors provide valuable guidance for recognizing high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.